Cipher PharmaceuticalsTSX:CPH +0.80%100 EBITDA Margin % is 54.43% as of Mar. 2026, which is 12% above its 10-year median of 48.52. GuruFocus rates TSX:CPH with a GF Score™ of 100/100 and a GF Value™ of C$17.03 (Fairly Valued). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Cipher Pharmaceuticals ranks better than 96.75% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cipher Pharmaceuticals EBITDA Margin % Related Terms
Cipher Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cipher Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipher Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cipher Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipher Pharmaceuticals (TSX:CPH) has a EBITDA Margin % of 54.43% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cipher Pharmaceuticals and its competitors. This is 12% above median its historical median of 48.52. Over the past decade, Cipher Pharmaceuticals' EBITDA Margin % has ranged from 21.35 to 62.71. According to the industry distribution chart, Cipher Pharmaceuticals ranks #31 out of 955 companies in the Drug Manufacturers industry, placing it in the top 3.2%.
Is Cipher Pharmaceuticals' EBITDA Margin % too high?
Cipher Pharmaceuticals' current EBITDA Margin % of 54.43% is 12% above median its 10-year median of 48.52. Over the past 10 years, this metric has ranged from a low of 21.35 to a high of 62.71. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Cipher Pharmaceuticals' value of 54.43% is 339.3% above this industry median. Based on the distribution chart, Cipher Pharmaceuticals ranks #31 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cipher Pharmaceuticals has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipher Pharmaceuticals ranks #31 out of 955 companies for EBITDA Margin %. This places Cipher Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Cipher Pharmaceuticals' value of 54.43% is 339.3% above this benchmark. Historically, Cipher Pharmaceuticals' own EBITDA Margin % has ranged from 21.35 to 62.71 over the past decade. While the company's 10-year median is 48.52 vs. the industry median of 12.39, Cipher Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipher Pharmaceuticals's current EBITDA Margin % of 54.43% is 339.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cipher Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipher Pharmaceuticals's current EBITDA Margin % is 54.43%, which is 12% above median its own 10-year median of 48.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (TSX:CPH) is currently considered Fairly Valued. The stock's GF Value™ is C$17.03, compared to a current price of C$16.47 — trading 3.3% below its estimated fair value. The current EBITDA Margin % is 54.43%, which is 12% above median its 10-year median of 48.52 and 339.3% above the Drug Manufacturers industry median of 12.39. Cipher Pharmaceuticals' overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cipher Pharmaceuticals (TSX:CPH), the current EBITDA Margin % is 54.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipher Pharmaceuticals (TSX:CPH) Overvalued in 2026?
Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued.
The current stock price of C$16.47 is trading 3.3% below its estimated GF Value™ of C$17.03.
GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.
Key valuation signals for TSX:CPH:
EBITDA Margin %: 54.43% (12% above median its 10-year median of 48.52)
GF Value™: C$17.03 vs. price of C$16.47 (3.3% below fair value)
Industry Position: 339.3% above the Drug Manufacturers median (#31 of 955)
No single metric tells the full story. See the TSX:CPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
100GF Score
Get the complete analysis for TSX:CPH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:CPH has been successfully added to your 
